Dendritic cell-based therapeutics for breast cancer

Breast Disease

Volumn 20, Issue , 2004, Pages 65-71

  Pilon Thomas, Shari A ^a   Verhaegen, Monique E ^b   Mulé, James J ^a  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; ANTINEOPLASTIC AGENT; COMPLEMENTARY DNA; EPIDERMAL GROWTH FACTOR RECEPTOR 2; INTERLEUKIN 2; MUCIN 1; PEPTIDE; RETROVIRUS VECTOR; RNA; TUMOR ANTIGEN; TUMOR CELL VACCINE; TUMOR NECROSIS FACTOR ALPHA;

ADOPTIVE IMMUNOTHERAPY; ANTIGEN PRESENTING CELL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CLINICAL TRIAL; DENDRITIC CELL; DRUG EFFICACY; DRUG FEVER; DRUG MEGADOSE; DRUG POTENTIATION; DRUG SAFETY; GENETIC TRANSFECTION; HUMAN; IMMUNE RESPONSE; IMMUNOREACTIVITY; IMMUNOSTIMULATION; LYMPHADENITIS; NONHUMAN; PAIN; PHENOTYPE; PRIORITY JOURNAL; T LYMPHOCYTE; TUMOR IMMUNITY; TUMOR REGRESSION; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY;

EID: 10044238145     PISSN: 08886008     EISSN: None     Source Type: Journal    
DOI: 10.3233/BD-2004-20108     Document Type: Article

References (44)

1. R.M. Steinman, The dendritic cell system and its role in immunogenicity, Annu. Rev. Immunol. 9 (1991), 271-296.
2. J. Banchereau and R. Steinman, Dendritic cells and the control of immunity, Nature 392 (1998), 245-252.
3. P.A. Cohen, P.J. Cohen, S. Rosenberg and J.J. Mulé, CD4+ T-cells from mice immunized to syngeneic sarcoma recognize distinct non-shared tumor antigens, Cancer Research 54 (1994), 1055-1058.
4. R.C. Fields, K. Shimizu and J.J. Mulé, Murine dendritic cells pulsed with whole tumor lysates mediate potent anti-tumor immune responses in vitro and in vivo, Proc. Natl. Acad. Sci. USA 95 (1998), 9482-9487.
5. A. Porgador, D. Snyder and E. Gilboa, Induction of antitumor immunity using bone marrow generated dendritic cells, Journal of Immunology 156 (1996), 2918-2926.
6. J.I. Mayordomo, T. Zorina, W.J. Storkus, L. Zitvogel, M.D. Garcis-Prats, A.B. DeLeo and M.T. Lotze, Bone marrow-derived dendritic cells serve as potent adjuvants for peptide-based antitumor vaccines, Stem Cells 15 (1996), 94-103.
7. R. Maldonado-Lopez, T. DeSmedt, P. Michel, J. Godfroid, B. Pajak, C. Heirman, K. Thielemans, O. Leo, J. Urbain and M. Moser, CD8a+ and CD8a- subclassed of dendritic cells direct the development of distinct T helper cells in vivo, J. Exp. Med. 189 (1999), 587-592.
8. B. Pulendran, J.L. Smith, G. Caspary, K. Brasel, D. Pettit, E. Maraskovsky and C.R. Maliszewski, Distinct dendritic cell subsets differentially regulate the class of immune response in vivo, Proc. Natl. Acad. Sci. USA 96 (1999), 1033-1041.
9. R. Steinman, S. Turley, I. Mellman and K. Inaba, The induction of tolerance by dendritic cells that have captured apoptotic cells, J. Exp. Med. 191 (2000), 411-416.
10. F.D. Finkelman, A. Lees, R. Birnbaum, W.C. Gause and S.C. Morris, Dendritic cells can present antigen in vivo in a tolerogenic or immunogenic fashion, Journal of Immunology 157 (1996), 1406-1414.
11. A.J. Engering, M. Cella, D.M. Fluitsma, E.C. Hoefsmit, A. Lanzavecchia and J. Pieters, Mannose receptor mediated antigen uptake and presentation in human dendritic cells, Adv Exp Med Biol 417 (1997), 183-187.
12. K.A. Berlyn, B. Schultes, B. Leveugle, A.A. Noujaim, R.B. Alexander and D.L. Mann, Generation of CD4(+) and CD8(+) T lymphocyte responses by dendritic cells armed with PSA/anti-PSA (antigen/antibody) complexes, Clin Immunol 101 (2001), 276-283.
13. A.M. Kalergis and J.V. Ravetch, Inducing tumor immunity through the selective engagement of activating Fcgamma receptors on dendritic cells, J. Exp. Med. 195 (2002), 1653-1659.
14. K. Inaba, M. Inaba, N. Romani, H. Aya, M. Deguchi, S. Ikehara, S. Muramatsu and R. Steinman, Generation of large numbers of dendritic cells from mouse bone marrow cultures supplemented with granulocyte/macrophage colony-stimulating factor, J. Exp. Med. 176 (1992), 1693-1702.
15. N. Romani, D. Reider, M. Heuer, S. Ebner, E. Kampgen, B. Eibl, D. Niederwieser and G. Schuler, Generation of mature dendritic cells from human blood. An improved method with special regard to clinical applicability, J Immunol Methods 196 (1996), 137-151.
16. H. Strobl, E. Riedl, C. Scheinecker, C. Bello-Fernandez, W.F. Pickl, O. Majdic and W. Knapp, TGF-beta 1 dependent generation of LAG+ dendritic cells from CD34+ progenitors in serum-free media, Adv Exp Med Biol 417 (1997), 161-165.
17. I.S. Grewel and R.A. Flavell, The role of CD40 ligand in costimulation and T-cell activation, Immunol Rev 153 (1996 , 85-106.
18. M. Cella, D. Scheidegger, K. Palmer-Lehmann, P. Lane, A. Lanzavecchia and G. Alber, Ligation of CD40 on dendritic cells triggers production of high levels of interleukin-12 and enhances T cell stimulatory capacity: T-T help via APC activation, J. Exp. Med. 182 (1996), 747-752.
19. M. Cella, F. Sallusto and A. Lanzavecchia, Origin, maturation, and antigen presenting function of dendritic cells, Curr Opin Immunol 9 (1997), 10-16.
20. M.T. Lotze, Getting to the source: Dendritic cells as therapeutic reagents for the treatment of patients with cancer, Ann Surg 226 (1997), 6-16.
21. F.O. Nestle, S. Alijagic, M. Gilliet, Y. Sun, S. Grabbe, R. Drummer, G. Burg and D. Schadendorf, Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells, Nature Medicine 4 (1998), 328-332.
22. K.A. Candido, K. Shimizu, J.C. McLaughlin, R. Kunkel, J.A. Fuller, B.G. Redman, E.K. Thomas, B.J. Nickoloff and J.J. Mule, Local administration of dendritic cells inhibits established breast tumor growth: Implications for apoptosis-inducing agents, Cancer Res 61 (2001), 228-236.
23. P.L. Triozzi, R. Khurram, W.A. Aldrich, M.J. Walker, J.A. Kim and S. Jaynes, Intratumoral injection of dendritic cells derived in vitro in patients with metastatic cancer, Cancer 89 (2000), 2646-2654.
24. G. Stingl and P.R. Bergstresser, Dendritic cells: A major story unfolds, Immunol Today 16 (1995), 330-333.
25. P.J. Cohen, P.A. Cohen, S.A. Rosenberg, S.I. Katz and J.J. Mule, Murine epidermal Langerhans cells and splenic dendritic cells present tumor-associated antigens to primed T cells, Eur. J. Immunol. 24 (1994), 315-319.
26. L. Jenne, J.F. Arrighi, H. Jonuleit, J.H. Saurat and C. Hauser, Dendritic cells containing apoptotic melanoma cells prime human CD8+ T cells for efficient tumor cell lysis, Cancer Res 60 (2000), 4446-4452.
27. S.K. Nair, D. Boczkowski, M. Morse, R.I. Cumming, H.K. Lyerly and E. Gilboa, Induction of primary carcinoembryonic antigen (CEA)-specific cytotoxic T lymphocytes in vitro using human dendritic cells transfected with RNA, Nat Biotechnol 16 (1998), 364-369.
28. D. Boczkowski, S.K. Nair, D. Snyder and E. Gilboa, Dendritic cells pulsed with RNA are potent antigen-presenting cells in vitro and in vivo, J. Exp. Med. 184 (1996), 465-472.
29. D.J. Slamon, W. Godolphin, L.A. Jones, J.A. Holt, S.G. Wong, D.E. Keith, W.J. Levin, S.G. Stuart, J. Udove, A. Ullrich and M.F. Press, Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer, Science 244 (1989), 707-712.
30. D.J. Slamon, G.M. Clark, S.G. Wong, W.J. Levin, A. Ullrich and W.L. McGuire, Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene, Science 235 (1987), 177-181.
31. G.E. Peoples, P.S. Goedegebuure, R. Smith, D.C. Linehan, I. Yoshino and T.J. Eberlein, Breast and ovarian cancer-specific cytotoxic T lymphocytes recognize the same HER2/neu - derived peptide, Proc. Natl. Acad. Sci. USA 92 (1995), 432-436.
32. P. Brossart, K.S. Heinrich, G. Stuhler, L. Behnke, V.L. Reichardt, S. Stevanovic, A. Muhm, H.G. Rammensee, L. Kanz and W. Brugger, Identification of HLA-A-2 restricted T-cell epitopes derived from the MUC1 tumor antigen for broadly applicable vaccine therapies, Blood 93 (1999), 4309-4317.
33. P. Brossart, S. Wirths, G. Stuhler, V.L. Reichardt and W. Brugger, Induction of cytotoxic T-lymphocyte responses in vivo after vaccinations with peptide-pulsed dendritic cells, Blood 96 (2000), 3102-3108.
34. W. Asavaroengchai, Y. Kotera and J.J. Mulé, Tumor lysate-pulsed dendritic cells can elicit an effective antitumor immune response during early lymphoid recovery, Proc. Natl. Acad. Sci. USA 99 (2002), 931-936.
35. R. Kass, J. Agha, S. Bellone, M. Palmier, S. Cane, E. Bignotti, R. Henry-Tillman, L. Hutchins, M.J. Cannon, S. Klimberg and A.D. Santin, In vitro induction of tumor-specific HLA class I - restricted CD8+ cytotoxic T lymphocytes from patients with locally advanced breast cancer by tumor antigen-pulsed autologous dendritic cells, J Surg Res 112 (2003), 189-197.
36. M. Lindner and V. Schirrmacher, Tumour-cell-dendritic cell fusion for cancer immunotherapy: Comparison of therapeutic efficiency of polyethylen-glycol versus electro-fusion protocols, Eur J Clin Invest 32 (2002), 207-217.
37. D. Avigan, Fusions of breast cancer and dendritic cells as a novel cancer vaccine, Clin Breast Cancer 3 (2003), S158-163.
38. G. Pecher, A. Haring, L. Kaiser and E. Thiel, Mucin gene (MUC1) transfected dendritic cells as vaccine: Results of a phase I/II clinical trial, Cancer Immunology, Immunotherapy 51 (2002), 669-673.
39. M.R. Muller, F. Grunebach, A. Nencioni and P. Brossart, Transfection of dendritic cells with RNA induces CD4- and CD8- mediated T cell immunity against breast carcinomas and reveals the immunodominance of presented T cell epitopes, Journal of Immunology 170 (2003), 5892-5896.
40. C.M. zum Buschenfelde, J. Metzger, C. Hermann, N. Nicklisch, C. Peschel and H. Bernhard, The generation of both T killer and Th cell clones specific for the tumor-associated antigen HER2 using retrovirally transduced dendritic cells, J. Immunol. 167 (2001), 1712-1719.
41. C.L. Efferson, J. Schickli, B.K. Ko, K. Kawano, S. Mouzi, P. Palese and C.G. Ioannides, Activation of tumor antigen-specific cytotoxic T lymphocytes (CTLs) by human dendritic cells infected with an attenuated influenza A virus expressing a CTL epitope derived from the HER-2/neu proto-oncogene, J Virol 77 (2003), 7411-7424.
42. Y. Chen, P. Emtage, Q. Zhu, R. Foley, W. Muller, M. Hitt, J. Gauldie and Y. Wan, Induction of ErbB-2/neu-specific protective and therapeutic antitumor immunity using genetically modified dendritic cells: Enhanced efficiency by cotransduction of gene encoding IL-12, Gene Therapy 8 (2001), 316-323.
43. B. Yu, S. Kusmartsev, F. Cheng, M. Paolini, Y. Nefedova, E. Sotomayor and D. Gabrilovich, Effective combination of chemotherapy and dendritic cell administration for the treatment of advanced-stage experimental breast cancer, Clinical Cancer Research 9 (2003), 285-294.
44. M.A. Morse, T.M. Clay, K. Colling, K.H. Grabstein, M.A. Cheever and H.K. Lyerly, Her2 dendritic cell vaccines, Clin Breast Cancer 3 (2003), S164-172.